Myriad Genetics (LTS:0K3W) Current Accrued Expense : $36.2 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Myriad Genetics Current Accrued Expense?

Myriad Genetics's Current Accrued Expense for the quarter that ended in Mar. 2024 was $36.2 Mil.

Myriad Genetics's quarterly Current Accrued Expense declined from Sep. 2023 ($89.7 Mil) to Dec. 2023 ($39.5 Mil) and declined from Dec. 2023 ($39.5 Mil) to Mar. 2024 ($36.2 Mil).

Myriad Genetics's annual Current Accrued Expense declined from Dec. 2021 ($89.9 Mil) to Dec. 2022 ($29.0 Mil) but then increased from Dec. 2022 ($29.0 Mil) to Dec. 2023 ($39.5 Mil).

Myriad Genetics Current Accrued Expense Historical Data

The historical data trend for Myriad Genetics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Current Accrued Expense Chart

Myriad Genetics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

30.50

17.20

89.90

29.00

39.50

Myriad Genetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															29.40	105.30	89.70	39.50	36.20

Myriad Genetics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Myriad Genetics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics (LTS:0K3W) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (LTS:0K3W) » Definitions » Current Accrued Expense

Comparable Companies

NEO TWST VCYT NEOG GH SHC OPK LAB CDNA CSTL TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

MYGN:USA MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics (LTS:0K3W) Headlines

No Headlines